Nearly 90 recent medications and formulations were added to the German pharmacopoeia, known as the Gelbe Liste, as of February 15, 2026, according to an announcement from the Informationsstelle für Arzneispezialitäten. The updates include two antibody therapies, Ziihera and Teizeild, a higher dosage of Ozempic – 2mg – and Lentocillin, an antibiotic currently facing supply constraints.
Ziihera is a powder concentrate for infusion, although Teizeild is a concentrate also intended for intravenous administration. Both are described as innovative antibody therapies. The introduction of a 2mg strength of Ozempic expands treatment options for patients utilizing the medication. Lentocillin’s inclusion in the Gelbe Liste acknowledges ongoing delivery issues with the drug.
The Gelbe Liste notes that access to the full details of these new additions is restricted to medical professionals, requiring registration on the platform. This is standard practice for the Gelbe Liste, which serves as a key resource for healthcare providers in Germany.
Recent updates to the Gelbe Liste have also included significant changes on February 1, 2026, with over 160 new drugs introduced, featuring a new Jivi strength, Atomoxetin capsules, Brensocatib, and updated Remsima formulations. On January 1, 2026, the Gelbe Liste added a subcutaneous immunoglobulin, an FcRn blocker for myasthenia gravis, and an ultra-short-acting benzodiazepine for procedural sedation.
The Gelbe Liste’s announcement on February 15th follows a period of substantial pharmaceutical updates in Germany, with over 100 new drugs appearing on the market as of January 15, 2026.